<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469049758</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132827.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920301xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF02973993</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF02973993</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">El-Naggar</subfield>
   <subfield code="D">Wael</subfield>
   <subfield code="u">Department of Microbiology, Faculty of Pharmacy, Mansoura University, 35516, Mansoura, Egypt</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Effect of salicylate on antibacterial activity of different antibiotics</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Wael El-Naggar]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Susceptibility ofPseudomonas aeruginosa, Staphylococcus aureus, andBacillus subtilis to gentamicin and cefotaxime was affected by salicylaye. In presence of salicylaye (15 mM) and gentamicin (1.0 ug/ml), log efficiency of plating (log E.O.P.s) for the tested bacteria were −1.24, −2.17 and −1.66 respectively. The activity of cefotaxime againstBacillus subtilis was reduced (log E.O.P.=1.33). The highest potentiating effects of salicylaye were shown when using gentamicin againstStaphylococcus aureus, cefotaxime againstPs. aeruginosa, log E.O.P.s were −3.0, and −2.4, respectively. On the other hand, no significant effects were detected with cefotaxime againstStaphylococcus aureus (log E.O. P.=−0.04). No significant killing was shown in presence of gentamicin or salicylaye alone. There was no significant effect for salicylaye on MICs (By broth dilution) could be observed except in case of gentamicin againstStaphylococcus aureus, which was reduced from 0.02 ug/ml to 0.0012 ug/ml. These results raise the concern that high concentrations of salicylaye in patients might interfere with antibiotic therapies.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">The Pharmaceutical Society of Korea, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Salicylate</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">efficiency of plating</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">gentamycin</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">cefotaxime</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Archives of Pharmacal Research</subfield>
   <subfield code="d">Pharmaceutical Society of Korea</subfield>
   <subfield code="g">15/1(1992-03-01), 99-103</subfield>
   <subfield code="x">0253-6269</subfield>
   <subfield code="q">15:1&lt;99</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12272</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF02973993</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF02973993</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">El-Naggar</subfield>
   <subfield code="D">Wael</subfield>
   <subfield code="u">Department of Microbiology, Faculty of Pharmacy, Mansoura University, 35516, Mansoura, Egypt</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Archives of Pharmacal Research</subfield>
   <subfield code="d">Pharmaceutical Society of Korea</subfield>
   <subfield code="g">15/1(1992-03-01), 99-103</subfield>
   <subfield code="x">0253-6269</subfield>
   <subfield code="q">15:1&lt;99</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12272</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
